Literature DB >> 30105874

Change of miRNA expression profiles in patients with knee osteoarthritis before and after celecoxib treatment.

Zhao Dong1, Honghui Jiang1, Xiaofei Jian1, Weiguo Zhang1.   

Abstract

BACKGROUND: This study aimed to investigate the change of circulating miRNA expression profiles in knee osteoarthritis (OA) patients before and after celecoxib treatment.
METHODS: Two hundred and eighteen knee OA patients underwent celecoxib treatment for 6 weeks were enrolled. Plasma samples were obtained at baseline (W0) and at W6, and treatment efficacy were assessed by WOMAC index. In the exploration stage, miRNA expression profiles in plasma before and after treatment from 6 patients were detected by microarray. Subsequently, in the validation stage, 10 top differentially expressed miRNAs (DEMs) after and before treatment in microarray were further validated in all 218 patients by qPCR.
RESULTS: In the exploration stage, patients after treatment could be distinguished from them before treatment by miRNAs expression profiles by PCA plot and heatmap analysis, and 45 up-regulated and 48 down-regulated miRNAs were identified by volcano plot. In the validation stage, miR-126-5p and miR-320a levels increased at W6 compared to W0, while miR-155-5p and miR-146a-5p levels decreased. WOMAC pain/stiffness/physical function scores were all decreased at W6 compared to W0, and 71% of patients achieved clinical response. The increase of miR-126-5p expression (W6-W0) in clinical responders was much larger compared to nonclinical responders. And miRNA-320a level declined in nonclinical responders while increased in clinical responders. Conversely, miRNA-146a-5p level increased in nonclinical responders while decreased in clinical responders.
CONCLUSION: Circulating miRNA expression profiles act as important roles in knee OA patients underwent celecoxib treatment, and miR-126-5p, miR-320a as well as miR-146a-5p might correlate with treatment response to celecoxib.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  celecoxib; knee osteoarthritis; microRNAs; profile

Mesh:

Substances:

Year:  2018        PMID: 30105874      PMCID: PMC6430337          DOI: 10.1002/jcla.22648

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  27 in total

1.  Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association.

Authors:  R Altman; E Asch; D Bloch; G Bole; D Borenstein; K Brandt; W Christy; T D Cooke; R Greenwald; M Hochberg
Journal:  Arthritis Rheum       Date:  1986-08

2.  Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis.

Authors:  Bruno R da Costa; Stephan Reichenbach; Noah Keller; Linda Nartey; Simon Wandel; Peter Jüni; Sven Trelle
Journal:  Lancet       Date:  2017-07-08       Impact factor: 79.321

3.  microRNA expression pattern and its alteration following celecoxib intervention in human colorectal cancer.

Authors:  Wei Chang Chen; Mao Song Lin; Yu Lan Ye; Heng Jun Gao; Zhen Yun Song; Xiao Ying Shen
Journal:  Exp Ther Med       Date:  2012-03-30       Impact factor: 2.447

4.  Regulation of miRNA-146a and miRNA-150 Levels by Celecoxib in Premalignant Lesions of K14-HPV16 Mice.

Authors:  Rui M Gil DA Costa; Rita Araújo; Joana M O Santos; Mara Fernandes; Tiago Neto; Hugo Sousa; Joana Ribeiro; Margarida M S M Bastos; Paula A Oliveira; Diogo Carmo; Fátima Casaca; Sandra Silva; Carlos Lopes; Rui Medeiros
Journal:  Anticancer Res       Date:  2017-06       Impact factor: 2.480

5.  The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells.

Authors:  Yoshimasa Saito; Hidekazu Suzuki; Hiroyuki Imaeda; Juntaro Matsuzaki; Kenro Hirata; Hitoshi Tsugawa; Sana Hibino; Yae Kanai; Hidetsugu Saito; Toshifumi Hibi
Journal:  Int J Cancer       Date:  2012-10-17       Impact factor: 7.396

6.  miR-140-5p/miR-149 Affects Chondrocyte Proliferation, Apoptosis, and Autophagy by Targeting FUT1 in Osteoarthritis.

Authors:  Zi Wang; Jialei Hu; Yue Pan; Yujia Shan; Liqun Jiang; Xia Qi; Li Jia
Journal:  Inflammation       Date:  2018-06       Impact factor: 4.092

7.  MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis.

Authors:  Mariola Kurowska-Stolarska; Stefano Alivernini; Lucy E Ballantine; Darren L Asquith; Neal L Millar; Derek S Gilchrist; James Reilly; Michelle Ierna; Alasdair R Fraser; Bartosz Stolarski; Charles McSharry; Axel J Hueber; Derek Baxter; John Hunter; Steffen Gay; Foo Y Liew; Iain B McInnes
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-20       Impact factor: 11.205

Review 8.  Celecoxib for osteoarthritis.

Authors:  Livia Puljak; Ana Marin; Davorka Vrdoljak; Filipa Markotic; Ana Utrobicic; Peter Tugwell
Journal:  Cochrane Database Syst Rev       Date:  2017-05-22

9.  Celecoxib increases miR-222 while deterring aromatase-expressing breast tumor growth in mice.

Authors:  Tsz Yan Wong; Fengjuan Li; Shu-mei Lin; Franky L Chan; Shiuan Chen; Lai K Leung
Journal:  BMC Cancer       Date:  2014-06-12       Impact factor: 4.430

Review 10.  Efficacy and Safety of Celecoxib Therapy in Osteoarthritis: A Meta-Analysis of Randomized Controlled Trials.

Authors:  Chao Xu; Ke Gu; Yalikun Yasen; Yanjie Hou
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

View more
  10 in total

1.  Change of miRNA expression profiles in patients with knee osteoarthritis before and after celecoxib treatment.

Authors:  Zhao Dong; Honghui Jiang; Xiaofei Jian; Weiguo Zhang
Journal:  J Clin Lab Anal       Date:  2018-08-13       Impact factor: 2.352

2.  Optimizing Perioperative Use of Opioids: A Multimodal Approach.

Authors:  Maria F Ramirez; Brinda B Kamdar; Juan P Cata
Journal:  Curr Anesthesiol Rep       Date:  2020-09-07

Review 3.  Anesthetics may modulate cancer surgical outcome: a possible role of miRNAs regulation.

Authors:  Masashi Ishikawa; Masae Iwasaki; Atsuhiro Sakamoto; Daqing Ma
Journal:  BMC Anesthesiol       Date:  2021-03-09       Impact factor: 2.217

Review 4.  An Insight into miR-1290: An Oncogenic miRNA with Diagnostic Potential.

Authors:  Małgorzata Guz; Witold Jeleniewicz; Marek Cybulski
Journal:  Int J Mol Sci       Date:  2022-01-22       Impact factor: 5.923

5.  Altered small non-coding RNA expression profiles of extracellular vesicles in the prostatic fluid of patients with chronic pelvic pain syndrome.

Authors:  Bin Ouyang; Dayu Han; Zexin Guo; Junhong Deng; Weilong Li; Liangliang Huang; Jianming Liu; Zhouda Cai; Jun Bian; Shaoming Huang
Journal:  Exp Ther Med       Date:  2022-04-08       Impact factor: 2.447

6.  Circular RNA MELK Promotes Chondrocyte Apoptosis and Inhibits Autophagy in Osteoarthritis by Regulating MYD88/NF-κB Signaling Axis through MicroRNA-497-5p.

Authors:  Yingchi Zhang; Rui Lu; Xiaojian Huang; Enzhi Yin; Yong Yang; Chengla Yi; Hongbo You; Xianzhou Song; Xuefeng Yuan
Journal:  Contrast Media Mol Imaging       Date:  2022-07-30       Impact factor: 3.009

Review 7.  Anesthetics and Long Term Cancer Outcomes: May Epigenetics Be the Key for Pancreatic Cancer?

Authors:  Zhirajr Mokini; Alessandro Cama; Patrice Forget
Journal:  Medicina (Kaunas)       Date:  2022-08-14       Impact factor: 2.948

8.  LncRNA DNM3OS promotes proliferation and inhibits apoptosis through modulating IGF1 expression by sponging MiR-126 in CHON-001 cells.

Authors:  Di Ai; Fang Yu
Journal:  Diagn Pathol       Date:  2019-09-16       Impact factor: 2.644

Review 9.  The Clinical Potential of Circulating miRNAs as Biomarkers: Present and Future Applications for Diagnosis and Prognosis of Age-Associated Bone Diseases.

Authors:  Michela Bottani; Giuseppe Banfi; Giovanni Lombardi
Journal:  Biomolecules       Date:  2020-04-11

10.  MicroRNA-140-5p represses chondrocyte pyroptosis and relieves cartilage injury in osteoarthritis by inhibiting cathepsin B/Nod-like receptor protein 3.

Authors:  Lei Zhang; Jianjun Qiu; Jixiang Shi; Shaoyang Liu; Hanlin Zou
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.